A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 19 Nov 2020 Biomarkers information updated
- 23 Jul 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 24 Dec 2012 New source identified and integrated (06-138: Memorial Sloan-Kettering Cancer Center).